Massachusetts-based biotech start-up Rubius Therapeutics has raised $120m in a series B round led by parent company Flagship Pioneering; marking one of the highest sums raised in the end of the. Considerable interest surrounds the company's Rubius Erythrocyte Design platform, which manufactures significant amounts of red blood cells and re-engineers them at an early stage for different therapeutic purposes, from activating T-cells as part of a cancer immunotherapy to binding with tumour cells and triggering apoptosis - the natural death of cells that occurs during growth.
Massachusetts-based biotech start-up Rubius Therapeutics has raised $120m in a series B round led by parent company Flagship Pioneering; marking one of the highest sums raised in 2017. Considerable interest surrounds the company's Rubius Erythrocyte Design platform, which manufactures significant amounts of red blood cells and re-engineers them at an early stage for different therapeutic purposes, from activating T-cells as part of a cancer immunotherapy to binding with tumour cells and triggering apoptosis - the natural death of cells that occurs during growth.